AUROBINDO

PRESS RELEASE

Aurobindo Pharma Announces Licensing and Supply Agreements with AstraZeneca for Supply of Finished Dosage Products to Emerging Markets

Hyderabad, India. (6th September, 2010) - Aurobindo Pharma is pleased to announce that it has entered into licensing and supply agreements with AstraZeneca, one of the world's leading biopharmaceutical businesses, to supply several solid dosage and sterile products for Emerging Markets.

The agreements will support AstraZeneca's investment in Branded Generics sold in Emerging markets. These products fall under a broad range of important therapeutic segments such as Anti-Infectives, Cardiovascular System (CVS) and Central Nervous System (CNS). Financial terms are not disclosed.

Commenting on the alliance, Mr.P.V.Ramprasad Reddy, Chairman, Aurobindo Pharma said *"Aurobindo's proven track record in building strong, collaborative working relationships is a key driver for these strategic agreements with AstraZeneca which will accelerate our growth plans and support our earnings."*

Mr. Kaushik Banerjee, Head of Branded Generics Operations at AstraZeneca said: *"These agreements will enable us to extend the range of branded medicines we are able to offer patients in Emerging markets, where we see continued opportunities to grow our business."*

About Aurobindo Pharma:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC-South Africa, ANVISA-Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

About AstraZeneca:

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com